| 1 | Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study | 2.9 | 6 | Citations (PDF) |
| 2 | Consejos para escribir un manuscrito y publicarlo en una revista biomédica | 0.5 | 0 | Citations (PDF) |
| 3 | Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for
Helicobacter pylori
infection between 2013 and 2021: results from the European registry on
H. pylori
management (Hp-EuReg) | 16.8 | 34 | Citations (PDF) |
| 4 | Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU | 16.8 | 17 | Citations (PDF) |
| 5 | Proteomic Profiling of Extracellular Vesicles in Inflammatory Bowel Diseases | 4.4 | 4 | Citations (PDF) |
| 6 | Etrasimod: revisión de la eficacia y las perspectivas terapéuticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa | 0.5 | 5 | Citations (PDF) |
| 7 | Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review | 1.3 | 16 | Citations (PDF) |
| 8 | Tips and tricks for writing a manuscript to publish in a biomedical journal | 0.1 | 1 | Citations (PDF) |
| 9 | Characterization of the Regulatory Landscape in Crohn’s Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response | 2.9 | 2 | Citations (PDF) |
| 10 | Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study | 1.3 | 1 | Citations (PDF) |
| 11 | Effect of Tofacitinib on Hemostasis in Patients with Ulcerative Colitis: A Comparative Ex Vivo Study | 4.2 | 0 | Citations (PDF) |
| 12 | Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis | 0.1 | 0 | Citations (PDF) |
| 13 | Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU | 3.7 | 3 | Citations (PDF) |
| 14 | Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry | 2.5 | 0 | Citations (PDF) |
| 15 | Helicobacter pylori y enfermedad gástrica | 0.8 | 10 | Citations (PDF) |
| 16 | Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn’s disease: results from the phase 3 VIVID-1 study | 1.3 | 1 | Citations (PDF) |
| 17 | Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study | 3.2 | 3 | Citations (PDF) |
| 18 | Helicobacter pylori and gastric disease | 0.1 | 0 | Citations (PDF) |
| 19 | First-Line Prescriptions and Effectiveness of Helicobacter pylori Eradication Treatment in Ireland over a 10-Year Period: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg) | 4.1 | 3 | Citations (PDF) |
| 20 | Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora Study | 2.0 | 1 | Citations (PDF) |
| 21 | Las infecciones de transmisión sexual como diagnóstico diferencial de la enfermedad inflamatoria intestinal | 0.5 | 0 | Citations (PDF) |
| 22 | Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics | 0.5 | 7 | Citations (PDF) |
| 23 | Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis | 2.5 | 12 | Citations (PDF) |
| 24 | Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies | 1.3 | 5 | Citations (PDF) |
| 25 | Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn’s Disease Therapeutic Outcomes Assessed Clinically and Endoscopically | 1.3 | 16 | Citations (PDF) |
| 26 | New drugs for the treatment of IBD during conception, pregnancy, and lactation | 2.5 | 27 | Citations (PDF) |
| 27 | Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry | 1.3 | 18 | Citations (PDF) |
| 28 | Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn’s Disease: A National, Multicentre Study Based on ENEIDA Registry | 1.3 | 17 | Citations (PDF) |
| 29 | De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review | 1.3 | 23 | Citations (PDF) |
| 30 | Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management | 4.8 | 24 | Citations (PDF) |
| 31 | Reglas y consejos para desarrollar con éxito un estudio multicéntrico | 0.5 | 2 | Citations (PDF) |
| 32 | Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry | 3.2 | 1 | Citations (PDF) |
| 33 | Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α | 4.9 | 4 | Citations (PDF) |
| 34 | P551 Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study | 1.3 | 1 | Citations (PDF) |
| 35 | P121 Characterisation of the miRNAome in Crohn’s Disease patients reveals transcriptomic changes associated with tissue composition and drug treatment | 1.3 | 0 | Citations (PDF) |
| 36 | Sequential versus Standard Triple Therapy for First-Line Helicobacter pylori Eradication: An Update | 4.1 | 11 | Citations (PDF) |
| 37 | Helicobacter pylori Eradication Treatment in Older Patients | 3.2 | 11 | Citations (PDF) |
| 38 | Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus | 1.3 | 11 | Citations (PDF) |
| 39 | Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics | 0.1 | 0 | Citations (PDF) |
| 40 | Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study | 4.8 | 14 | Citations (PDF) |
| 41 | Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) | 3.7 | 22 | Citations (PDF) |
| 42 | Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis | 1.3 | 12 | Citations (PDF) |
| 43 | Sexually transmitted infections as a differential diagnosis of inflammatory bowel disease | 0.1 | 0 | Citations (PDF) |
| 44 | Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis | 2.1 | 11 | Citations (PDF) |
| 45 | Safety profile of
Helicobacter pylori
eradication treatments: literature review and updated data of the European Registry on
Helicobacter pylori
management (Hp-EuReg) | 2.6 | 11 | Citations (PDF) |
| 46 | Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management | 4.8 | 39 | Citations (PDF) |
| 47 | Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA | 4.9 | 7 | Citations (PDF) |
| 48 | Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply | 3.7 | 0 | Citations (PDF) |
| 49 | ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment | 1.3 | 129 | Citations (PDF) |
| 50 | ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment | 1.3 | 297 | Citations (PDF) |
| 51 | Tips and tricks for successfully conducting a multicenter study | 0.1 | 1 | Citations (PDF) |
| 52 | Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry | 3.7 | 11 | Citations (PDF) |
| 53 | Long Non-Coding RNAs and Their Potential Role as Biomarkers in Inflammatory Bowel Disease | 4.4 | 4 | Citations (PDF) |
| 54 | Common Mistakes in Managing Patients with Inflammatory Bowel Disease | 2.5 | 3 | Citations (PDF) |
| 55 | Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study | 3.7 | 5 | Citations (PDF) |
| 56 | Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis | 3.8 | 11 | Citations (PDF) |
| 57 | Reglas y consejos para ser un buen revisor por pares de manuscritos científicos | 0.5 | 10 | Citations (PDF) |
| 58 | Reply | 6.0 | 0 | Citations (PDF) |
| 59 | Empirical rescue treatment of
Helicobacter pylori
infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on
H. pylori
management (Hp-EuReg) | 16.8 | 10 | Citations (PDF) |
| 60 | Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management | 4.8 | 17 | Citations (PDF) |
| 61 | Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review | 1.3 | 55 | Citations (PDF) |
| 62 | Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe? | 1.3 | 25 | Citations (PDF) |
| 63 | ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease | 1.3 | 19 | Citations (PDF) |
| 64 | P779 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY) | 1.3 | 0 | Citations (PDF) |
| 65 | Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review | 2.9 | 26 | Citations (PDF) |
| 66 | Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study | 3.8 | 2 | Citations (PDF) |
| 67 | P611 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN’S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY) | 1.3 | 0 | Citations (PDF) |
| 68 | P431 A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence | 1.3 | 0 | Citations (PDF) |
| 69 | Tips and guidelines for being a good peer reviewer | 0.1 | 3 | Citations (PDF) |
| 70 | P058 Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients | 1.3 | 0 | Citations (PDF) |
| 71 | P024 Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 72 | Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD) | 3.0 | 4 | Citations (PDF) |
| 73 | 80 - EFICACIA Y SEGURIDAD DE LA MONITORIZACIÓN PROACTIVA DE NIVELES DE FÁRMACOS ANTI-TNF EN EL TRATAMIENTO DE MANTENIMIENTO DE PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL: REVISIÓN SISTEMÁTICA Y METAANÁLISIS | 0.5 | 0 | Citations (PDF) |
| 74 | Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study | 3.7 | 13 | Citations (PDF) |
| 75 | Development of a Prediction Model for Short-Term Remission of Patients with Crohn’s Disease Treated with Anti-TNF Drugs | 4.4 | 3 | Citations (PDF) |
| 76 | Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis | 4.4 | 17 | Citations (PDF) |
| 77 | Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management | 2.5 | 17 | Citations (PDF) |
| 78 | FiLaC� procedure for highly selected anal fistula patients: indications, safety and efficacy from an observational study at a tertiary referral center | 0.3 | 3 | Citations (PDF) |
| 79 | Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP | 2.5 | 7 | Citations (PDF) |
| 80 | Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s DiseaseDrugs, 2023, 83, 1179-1205 | 11.4 | 33 | Citations (PDF) |
| 81 | Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe | 2.1 | 2 | Citations (PDF) |
| 82 | Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg) | 4.1 | 4 | Citations (PDF) |
| 83 | Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
Helicobacter pylori
Management (Hp-EuReg) | 16.8 | 6 | Citations (PDF) |
| 84 | Comparison of the management of Helicobacter pylori infection between the older and younger European populations | 3.4 | 14 | Citations (PDF) |
| 85 | Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease | 3.4 | 2 | Citations (PDF) |
| 86 | Long Non-Coding RNA Signatures in the Ileum and Colon of Crohn’s Disease Patients and Effect of Anti-TNF-α Treatment on Their Modulation | 4.4 | 5 | Citations (PDF) |
| 87 | Room for Improvement in the Treatment of Helicobacter pylori Infection | 2.3 | 58 | Citations (PDF) |
| 88 | Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies | 6.0 | 36 | Citations (PDF) |
| 89 | ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment | 1.3 | 306 | Citations (PDF) |
| 90 | ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment | 1.3 | 930 | Citations (PDF) |
| 91 | V Spanish Consensus Conference on Helicobacter pylori infection treatment | 0.1 | 4 | Citations (PDF) |
| 92 | Hallmarks of the human intestinal microbiome on liver maturation and function | 4.2 | 31 | Citations (PDF) |
| 93 | V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori | 0.5 | 45 | Citations (PDF) |
| 94 | Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study | 22.8 | 89 | Citations (PDF) |
| 95 | Clinical characteristics and prognostic factors for Crohn’s disease relapses using natural language processing and machine learning: a pilot study | 1.3 | 29 | Citations (PDF) |
| 96 | Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry | 2.5 | 10 | Citations (PDF) |
| 97 | P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease | 1.3 | 1 | Citations (PDF) |
| 98 | Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey | 1.3 | 13 | Citations (PDF) |
| 99 | Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients | 2.4 | 8 | Citations (PDF) |
| 100 | Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study | 2.9 | 58 | Citations (PDF) |
| 101 | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) | 2.5 | 23 | Citations (PDF) |
| 102 | Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study] | 1.3 | 17 | Citations (PDF) |
| 103 | Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry | 1.3 | 11 | Citations (PDF) |
| 104 | Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series | 1.3 | 10 | Citations (PDF) |
| 105 | Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg) | 6.0 | 33 | Citations (PDF) |
| 106 | Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
TM
): a multidisciplinary perspective | 3.0 | 12 | Citations (PDF) |
| 107 | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity | 3.4 | 8 | Citations (PDF) |
| 108 | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg) | 2.5 | 21 | Citations (PDF) |
| 109 | Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis | 3.9 | 55 | Citations (PDF) |
| 110 | Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU | 2.5 | 4 | Citations (PDF) |
| 111 | Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies | 2.5 | 38 | Citations (PDF) |
| 112 | Differential Effects of Anti-TNFα and Anti-α4β7 Drugs on Circulating Dendritic Cells Migratory Capacity in Inflammatory Bowel Disease | 3.4 | 4 | Citations (PDF) |
| 113 | Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab | 2.5 | 10 | Citations (PDF) |
| 114 | European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice | 0.9 | 16 | Citations (PDF) |
| 115 | Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study | 2.5 | 5 | Citations (PDF) |
| 116 | The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn’s Disease | 4.4 | 11 | Citations (PDF) |
| 117 | Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII) | 2.5 | 2 | Citations (PDF) |
| 118 | Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease | 2.9 | 9 | Citations (PDF) |
| 119 | Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine | 6.0 | 17 | Citations (PDF) |
| 120 | Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry | 1.3 | 95 | Citations (PDF) |
| 121 | European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice | 4.8 | 71 | Citations (PDF) |
| 122 | European Registry onHelicobacter pylorimanagement (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients | 16.8 | 233 | Citations (PDF) |
| 123 | Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease | 2.9 | 13 | Citations (PDF) |
| 124 | The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review | 4.4 | 80 | Citations (PDF) |
| 125 | Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry | 1.3 | 70 | Citations (PDF) |
| 126 | Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease | 3.8 | 163 | Citations (PDF) |
| 127 | Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience | 1.7 | 4 | Citations (PDF) |
| 128 | Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg) | 0.7 | 79 | Citations (PDF) |
| 129 | DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study | 1.3 | 0 | Citations (PDF) |
| 130 | P277 Frequency and effectiveness of empirical anti-TNF dose intensification in Inflammatory Bowel Disease: systematic review with meta-analysis | 1.3 | 1 | Citations (PDF) |
| 131 | Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis | 2.5 | 23 | Citations (PDF) |
| 132 | Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract | 4.0 | 24 | Citations (PDF) |
| 133 | Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study | 3.7 | 22 | Citations (PDF) |
| 134 | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study | 2.5 | 10 | Citations (PDF) |
| 135 | Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study | 2.5 | 91 | Citations (PDF) |
| 136 | Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions | 3.8 | 12 | Citations (PDF) |
| 137 | Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg) | 2.0 | 4 | Citations (PDF) |
| 138 | Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience | 4.8 | 39 | Citations (PDF) |
| 139 | Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study) | 3.7 | 17 | Citations (PDF) |
| 140 | Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis | 0.9 | 165 | Citations (PDF) |
| 141 | The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg) | 4.1 | 11 | Citations (PDF) |
| 142 | Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection | 4.1 | 9 | Citations (PDF) |
| 143 | Challenges of independent clinical research | 0.1 | 0 | Citations (PDF) |
| 144 | Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg) | 4.1 | 106 | Citations (PDF) |
| 145 | Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease | 4.4 | 47 | Citations (PDF) |
| 146 | Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study) | 0.1 | 0 | Citations (PDF) |
| 147 | Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu | 2.5 | 17 | Citations (PDF) |
| 148 | Retos y desafíos de la investigación clínica independiente | 0.5 | 7 | Citations (PDF) |
| 149 | Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved | 6.6 | 17 | Citations (PDF) |
| 150 | The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU | 3.2 | 21 | Citations (PDF) |
| 151 | Derrame pericárdico asociado al tratamiento con mesalazina en un paciente con colitis ulcerosa | 0.5 | 2 | Citations (PDF) |
| 152 | European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain | 4.1 | 20 | Citations (PDF) |
| 153 | Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring | 4.4 | 20 | Citations (PDF) |
| 154 | Rifabutin for the Treatment of Helicobacter pylori Infection: A Review | 2.9 | 77 | Citations (PDF) |
| 155 | Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg) | 0.5 | 3 | Citations (PDF) |
| 156 | How to prepare a research proposal in the health science? | 0.1 | 4 | Citations (PDF) |
| 157 | Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnóstico de Helicobacter pylori (estudio Almatest) | 0.5 | 0 | Citations (PDF) |
| 158 | Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis | 0.1 | 0 | Citations (PDF) |
| 159 | ¿Cómo elaborar un proyecto de investigación en ciencias de la salud? | 0.5 | 8 | Citations (PDF) |
| 160 | Características epidemiológicas, clínicas y respuesta al tratamiento en 113 pacientes con colitis microscópica | 0.5 | 2 | Citations (PDF) |
| 161 | Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? | 2.5 | 73 | Citations (PDF) |
| 162 | Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review | 4.2 | 73 | Citations (PDF) |
| 163 | Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey | 1.3 | 4 | Citations (PDF) |
| 164 | Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti‐TNF‐α: results from the ENEIDA registry | 3.7 | 11 | Citations (PDF) |
| 165 | Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry | 2.9 | 33 | Citations (PDF) |
| 166 | Response to the Letter to the Editor: “Response to Infliximab After Loss of Response to Adalimumab in Crohn’s Disease” | 2.9 | 0 | Citations (PDF) |
| 167 | The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn’s Disease | 1.3 | 29 | Citations (PDF) |
| 168 | Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients | 6.0 | 83 | Citations (PDF) |
| 169 | ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment | 1.3 | 1,220 | Citations (PDF) |
| 170 | ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment | 1.3 | 701 | Citations (PDF) |
| 171 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento tópico en la colitis ulcerosa | 0.5 | 7 | Citations (PDF) |
| 172 | Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice | 1.3 | 250 | Citations (PDF) |
| 173 | Review – Treatment of Helicobacter pylori infection 2020 | 3.8 | 51 | Citations (PDF) |
| 174 | P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery | 1.3 | 0 | Citations (PDF) |
| 175 | P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib | 1.3 | 0 | Citations (PDF) |
| 176 | Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg) | 3.8 | 28 | Citations (PDF) |
| 177 | El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales) de GETECCU: diseño, monitorización y funciones | 0.5 | 66 | Citations (PDF) |
| 178 | Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review | 3.2 | 97 | Citations (PDF) |
| 179 | Reglas y consejos para ser un investigador de éxito | 0.5 | 14 | Citations (PDF) |
| 180 | Tips and guidelines for being a successful researcher | 0.1 | 1 | Citations (PDF) |
| 181 | Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain | 0.1 | 0 | Citations (PDF) |
| 182 | Early treatment with anti‐tumor necrosis factor agents improves long‐term effectiveness in symptomatic stricturing Crohn’s disease | 4.8 | 42 | Citations (PDF) |
| 183 | Errores en la atención de los pacientes con enfermedad inflamatoria intestinal: estudio «ERRATA» | 0.5 | 5 | Citations (PDF) |
| 184 | Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones | 4.2 | 29 | Citations (PDF) |
| 185 | Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection | 0.5 | 9 | Citations (PDF) |
| 186 | Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study | 2.5 | 32 | Citations (PDF) |
| 187 | A quick flow cytometry protocol to assess Helicobacter pylori viability | 1.7 | 5 | Citations (PDF) |
| 188 | P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis | 1.3 | 0 | Citations (PDF) |
| 189 | Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents | 2.5 | 21 | Citations (PDF) |
| 190 | Errors in the care of inflammatory bowel disease patients: “Errata” Study | 0.1 | 1 | Citations (PDF) |
| 191 | Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection | 0.1 | 1 | Citations (PDF) |
| 192 | Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease | 1.3 | 8 | Citations (PDF) |
| 193 | Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A ReviewDrugs, 2020, 80, 1085-1100 | 11.4 | 71 | Citations (PDF) |
| 194 | Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease | 3.7 | 25 | Citations (PDF) |
| 195 | Helicobacter pylorifirst‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry onH pylorimanagement (Hp‐EuReg) | 3.8 | 42 | Citations (PDF) |
| 196 | Endothelial
MT
1‐
MMP
targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis | 7.1 | 48 | Citations (PDF) |
| 197 | Recomendaciones del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) para el tratamiento de las fístulas perianales de la enfermedad de Crohn | 0.5 | 28 | Citations (PDF) |
| 198 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento | 0.5 | 16 | Citations (PDF) |
| 199 | P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU | 1.3 | 7 | Citations (PDF) |
| 200 | Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper | 1.3 | 107 | Citations (PDF) |
| 201 | Recommendations of the Crohn’s Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn’s disease | 0.1 | 6 | Citations (PDF) |
| 202 | Systematic review: gastric microbiota in health and disease | 3.7 | 163 | Citations (PDF) |
| 203 | P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study | 1.3 | 0 | Citations (PDF) |
| 204 | Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis | 0.1 | 0 | Citations (PDF) |
| 205 | Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry | 1.3 | 9 | Citations (PDF) |
| 206 | Helicobacter pylori “Test‐and‐Treat” strategy with urea breath test: A cost‐effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain—Results of the Hp‐Breath initiative | 3.8 | 38 | Citations (PDF) |
| 207 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad inflamatoria intestinal asociada a espondiloartritis | 0.5 | 10 | Citations (PDF) |
| 208 | Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial | 0.7 | 18 | Citations (PDF) |
| 209 | P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience | 1.3 | 0 | Citations (PDF) |
| 210 | Encuesta de adherencia al tratamiento en enfermedad inflamatoria intestinal. Estudio ENADEII | 0.5 | 5 | Citations (PDF) |
| 211 | Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit | 0.3 | 2 | Citations (PDF) |
| 212 | Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain | 0.5 | 1 | Citations (PDF) |
| 213 | The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions | 0.1 | 8 | Citations (PDF) |
| 214 | Alertas sobre la seguridad de las quinolonas: ¿debemos modificar su prescripción en el tratamiento de la infección por Helicobacter pylori | 0.5 | 3 | Citations (PDF) |
| 215 | Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg) | 3.8 | 77 | Citations (PDF) |
| 216 | Efficacy of tofacitinib treatment in ulcerative colitis | 0.1 | 3 | Citations (PDF) |
| 217 | Management and outcomes of patients with Crohn’s disease with first vs multiple surgeries: results from the PRACTICROHN study | 1.4 | 4 | Citations (PDF) |
| 218 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiología, diagnóstico y pronóstico | 0.5 | 16 | Citations (PDF) |
| 219 | Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease | 4.4 | 40 | Citations (PDF) |
| 220 | P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry | 1.3 | 0 | Citations (PDF) |
| 221 | Review: Treatment of Helicobacter pylori Infection 2019 | 3.8 | 48 | Citations (PDF) |
| 222 | P138 Prediction model to safely cease anti-TNF therapy in Crohn’s disease: individual patient data meta-analysis (IPD-MA) | 1.3 | 1 | Citations (PDF) |
| 223 | Increased risk of thiopurine‐related adverse events in elderly patients with IBD | 3.7 | 55 | Citations (PDF) |
| 224 | Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease | 3.2 | 5 | Citations (PDF) |
| 225 | Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified? | 0.1 | 2 | Citations (PDF) |
| 226 | DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU | 1.3 | 0 | Citations (PDF) |
| 227 | P526 Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY | 1.3 | 0 | Citations (PDF) |
| 228 | Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity | 22.6 | 210 | Citations (PDF) |
| 229 | Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study | 1.3 | 94 | Citations (PDF) |
| 230 | Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding | 3.7 | 26 | Citations (PDF) |
| 231 | Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry | 3.7 | 67 | Citations (PDF) |
| 232 | A network meta‐analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection | 4.8 | 50 | Citations (PDF) |
| 233 | EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain | 3.2 | 21 | Citations (PDF) |
| 234 | Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease | 1.3 | 25 | Citations (PDF) |
| 235 | Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions | 3.8 | 27 | Citations (PDF) |
| 236 | Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study | 1.3 | 52 | Citations (PDF) |
| 237 | Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa | 0.5 | 24 | Citations (PDF) |
| 238 | Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease | 2.6 | 12 | Citations (PDF) |
| 239 | P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease | 1.3 | 0 | Citations (PDF) |
| 240 | Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey | 0.1 | 2 | Citations (PDF) |
| 241 | Role of food proteins and bioactive peptides in inflammatory bowel disease | 15.1 | 79 | Citations (PDF) |
| 242 | P223 Efficacy and safety of tacrolimus in Crohn’s disease: a nationwide, multi-centric study from GETECCU | 1.3 | 0 | Citations (PDF) |
| 243 | P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry | 1.3 | 1 | Citations (PDF) |
| 244 | Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn’s patients: Results of the APPRECIA trial | 2.5 | 3 | Citations (PDF) |
| 245 | Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit | 0.9 | 1 | Citations (PDF) |
| 246 | Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori | 3.8 | 78 | Citations (PDF) |
| 247 | P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab | 1.3 | 0 | Citations (PDF) |
| 248 | P013 Novel immunomodulatory role of food bioactive peptide lunasin in the healthy human intestinal mucosa | 1.3 | 2 | Citations (PDF) |
| 249 | Páneurópai regiszter: a <i>Helicobacter pylori</i>-fertőzés kezelése. <i>Ferencvárosi adatok, 2013–2019</i> | 0.3 | 3 | Citations (PDF) |
| 250 | Empirical
Helicobacter pylori
rescue therapy: an 18‐year single‐centre study of 1200 patients | 0.8 | 14 | Citations (PDF) |
| 251 | Reply | 6.0 | 1 | Citations (PDF) |
| 252 | Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis | 0.1 | 4 | Citations (PDF) |
| 253 | Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial | 3.2 | 7 | Citations (PDF) |
| 254 | P809 Quality of care through the eyes of the patients in a Spanish inflammatory bowel disease Unit | 1.3 | 0 | Citations (PDF) |
| 255 | Systematic review with meta‐analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy | 3.7 | 44 | Citations (PDF) |
| 256 | ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review | 1.3 | 70 | Citations (PDF) |
| 257 | Manejo de la colitis ulcerosa aguda grave en España: Resultados de una encuesta sobre práctica clínica | 0.5 | 10 | Citations (PDF) |
| 258 | Differences between childhood‐ and adulthood‐onset inflammatory bowel disease: the CAROUSEL study from GETECCU | 3.7 | 44 | Citations (PDF) |
| 259 | Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract | 3.6 | 11 | Citations (PDF) |
| 260 | Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review | 1.3 | 63 | Citations (PDF) |
| 261 | Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients | 0.3 | 10 | Citations (PDF) |
| 262 | Mejora de la atención al paciente con enfermedad inflamatoria intestinal: Proyecto KOAN 2019, 14, | | 0 | Citations (PDF) |
| 263 | Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study | 0.7 | 165 | Citations (PDF) |
| 264 | P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU | 1.3 | 0 | Citations (PDF) |
| 265 | Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology | 0.1 | 3 | Citations (PDF) |
| 266 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease | 0.1 | 4 | Citations (PDF) |
| 267 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal | 0.5 | 46 | Citations (PDF) |
| 268 | Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia | 0.5 | 12 | Citations (PDF) |
| 269 | Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study | 3.7 | 74 | Citations (PDF) |
| 270 | Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases | 4.0 | 43 | Citations (PDF) |
| 271 | Validation of the ‘United Registries for Clinical Assessment and Research’ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease | 1.3 | 17 | Citations (PDF) |
| 272 | Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease | 2.5 | 33 | Citations (PDF) |
| 273 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inflamatoria intestinal | 0.5 | 37 | Citations (PDF) |
| 274 | Helicobacter Pylori Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study | 0.7 | 66 | Citations (PDF) |
| 275 | Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab | 16.8 | 150 | Citations (PDF) |
| 276 | Preguntas y errores en el diagnóstico y manejo de la anemia en pacientes con hemorragia digestiva | 0.5 | 7 | Citations (PDF) |
| 277 | European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease | 1.3 | 199 | Citations (PDF) |
| 278 | Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding | 0.1 | 5 | Citations (PDF) |
| 279 | P745 Switching between anti-TNF originator and biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review | 1.3 | 0 | Citations (PDF) |
| 280 | Improvement in Physicianʼs Global Assessment Within 2 Weeks in Patients With Ulcerative Colitis Treated With Tofacitinib | 0.7 | 0 | Citations (PDF) |
| 281 | Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry | 3.7 | 95 | Citations (PDF) |
| 282 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease | 0.1 | 4 | Citations (PDF) |
| 283 | Treatment ofHelicobacter pyloriinfection in 2018 | 3.8 | 51 | Citations (PDF) |
| 284 | Genetic variation analysis in a follow‐up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14 | 4.3 | 19 | Citations (PDF) |
| 285 | The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation | 2.9 | 55 | Citations (PDF) |
| 286 | Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review | 0.5 | 26 | Citations (PDF) |
| 287 | Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review | 0.1 | 2 | Citations (PDF) |
| 288 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal | 0.5 | 48 | Citations (PDF) |
| 289 | Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease | 1.3 | 21 | Citations (PDF) |
| 290 | Acute severe ulcerative colitis: State of the art treatment | 2.7 | 39 | Citations (PDF) |
| 291 | Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c−CCR2−CX3CR1− counterparts, are expanded in inflammatory bowel disease | 7.0 | 144 | Citations (PDF) |
| 292 | Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double‐blind, placebo‐controlled trial | 3.8 | 50 | Citations (PDF) |
| 293 | Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients | 2.1 | 29 | Citations (PDF) |
| 294 | La relación mentor-aprendiz en medicina | 0.5 | 27 | Citations (PDF) |
| 295 | Tratamiento actual de la infección por Helicobacter pylori | 0.8 | 6 | Citations (PDF) |
| 296 | Mentor–mentee relationship in medicine | 0.1 | 8 | Citations (PDF) |
| 297 | Current treatment of Helicobacter pylori infection | 0.1 | 1 | Citations (PDF) |
| 298 | Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment | 2.5 | 16 | Citations (PDF) |
| 299 | Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies | 3.8 | 100 | Citations (PDF) |
| 300 | Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry | 0.7 | 30 | Citations (PDF) |
| 301 | Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis | 11.4 | 25 | Citations (PDF) |
| 302 | Management of
Helicobacter pylori
infection—the Maastricht V/Florence Consensus Report | 16.8 | 2,711 | Citations (PDF) |
| 303 | Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study | 0.7 | 103 | Citations (PDF) |
| 304 | Enfermedad celíaca no respondedora: crisis celíaca vs. enfermedad celíaca refractaria con respuesta a corticoides | 0.5 | 4 | Citations (PDF) |
| 305 | Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection | 0.5 | 19 | Citations (PDF) |
| 306 | Letter: the definition of budesonide dependence in microscopic colitis | 3.7 | 3 | Citations (PDF) |
| 307 | Ustekinumab en el tratamiento de la enfermedad de Crohn | 0.5 | 17 | Citations (PDF) |
| 308 | Non-responsive coeliac disease: Coeliac crisis vs. refractory coeliac disease with response to corticosteroids | 0.1 | 0 | Citations (PDF) |
| 309 | Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease | 2.5 | 31 | Citations (PDF) |
| 310 | Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn’s Disease | 2.1 | 26 | Citations (PDF) |
| 311 | Treatment of Helicobacter pylori infection 2017 | 3.8 | 28 | Citations (PDF) |
| 312 | Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment forHelicobacter pyloriinfection | 3.0 | 10 | Citations (PDF) |
| 313 | Erratum to “IV Spanish Consensus Conference on Helicobacter pylori infection treatment” <[Gastroenterol Hepatol 39 (2016) 697–721]> | 0.1 | 3 | Citations (PDF) |
| 314 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn | 0.5 | 33 | Citations (PDF) |
| 315 | Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease | 1.3 | 171 | Citations (PDF) |
| 316 | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial | 0.5 | 12 | Citations (PDF) |
| 317 | Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain | 0.7 | 20 | Citations (PDF) |
| 318 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease | 0.1 | 6 | Citations (PDF) |
| 319 | Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis | 2.9 | 75 | Citations (PDF) |
| 320 | Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease | 1.9 | 21 | Citations (PDF) |
| 321 | Ustekinumab to treat Crohn's disease | 0.1 | 5 | Citations (PDF) |
| 322 | Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection | 0.1 | 2 | Citations (PDF) |
| 323 | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial | 0.1 | 0 | Citations (PDF) |
| 324 | Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer | 2.3 | 25 | Citations (PDF) |
| 325 | Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis | 2.9 | 2 | Citations (PDF) |
| 326 | Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease | 2.9 | 19 | Citations (PDF) |
| 327 | Current concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis Group | 3.7 | 62 | Citations (PDF) |
| 328 | Monitoring thiopurine metabolites in inflammatory bowel disease | 2.0 | 28 | Citations (PDF) |
| 329 | IV Spanish Consensus Conference on Helicobacter pylori infection treatment | 0.1 | 31 | Citations (PDF) |
| 330 | Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab | 5.1 | 14 | Citations (PDF) |
| 331 | Efficacy and safety of vedolizumab in the treatment of ulcerative colitis | 0.1 | 2 | Citations (PDF) |
| 332 | Letter: switching from one to another anti‐tumour necrosis factor alpha agent, and the risks of an overlap of exposure – authors' reply | 3.7 | 0 | Citations (PDF) |
| 333 | Enfermedades relacionadas con la infección por Helicobacter pylori | 0.5 | 6 | Citations (PDF) |
| 334 | Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease | 0.5 | 45 | Citations (PDF) |
| 335 | Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa | 0.5 | 7 | Citations (PDF) |
| 336 | Outcome after a dose “de-intensification” strategy with anti-TNF drugs in patients with Crohn's disease | 0.1 | 0 | Citations (PDF) |
| 337 | The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults | 0.9 | 842 | Citations (PDF) |
| 338 | IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori | 0.5 | 102 | Citations (PDF) |
| 339 | Urine metabolome profiling of immune-mediated inflammatory diseases | 7.1 | 125 | Citations (PDF) |
| 340 | Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease | 0.1 | 1 | Citations (PDF) |
| 341 | New molecules in the treatment of inflammatory bowel disease | 0.1 | 4 | Citations (PDF) |
| 342 | Letter: Helicobacter pylori infection and eosinophilic oesophagitis ‐ causal or casual inverse association? | 3.7 | 2 | Citations (PDF) |
| 343 | Treatment of <i>Helicobacter pylori</i> infection 2016 | 3.8 | 12 | Citations (PDF) |
| 344 | Sequential versus standard triple first-line therapy forHelicobacter pylorieradication | 2.1 | 43 | Citations (PDF) |
| 345 | Letter: anti‐TNF in steroid‐dependent ulcerative colitis ‐ are the available data enough? | 3.7 | 0 | Citations (PDF) |
| 346 | Letter: oral low‐dose methotrexate for collagenous colitis – authors’ reply | 3.7 | 0 | Citations (PDF) |
| 347 | Ustekinumab for the Treatment of Refractory Crohnʼs Disease | 2.9 | 162 | Citations (PDF) |
| 348 | Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole forHelicobacter pylorifirst-line treatment | 3.1 | 48 | Citations (PDF) |
| 349 | Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain | 0.1 | 1 | Citations (PDF) |
| 350 | Maintenance therapy options for ulcerative colitis | 2.1 | 28 | Citations (PDF) |
| 351 | Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection | 3.2 | 36 | Citations (PDF) |
| 352 | Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross‐sectional study) | 4.8 | 8 | Citations (PDF) |
| 353 | Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow‐up multicenter study | 2.5 | 110 | Citations (PDF) |
| 354 | Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study | 0.7 | 56 | Citations (PDF) |
| 355 | Nuevas moléculas en el tratamiento de la enfermedad inflamatoria intestinal | 0.5 | 7 | Citations (PDF) |
| 356 | Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study | 2.5 | 43 | Citations (PDF) |
| 357 | Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent | 2.5 | 14 | Citations (PDF) |
| 358 | Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn’s Disease | 1.3 | 36 | Citations (PDF) |
| 359 | Letter: management of post‐operative Crohn's disease ‐ thiopurines vs adalimumab | 3.7 | 1 | Citations (PDF) |
| 360 | The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis | 0.7 | 190 | Citations (PDF) |
| 361 | Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study | 2.5 | 52 | Citations (PDF) |
| 362 | Outcome after a dose “de-intensification” strategy with anti-TNF drugs in patients with Crohn's disease | 0.5 | 11 | Citations (PDF) |
| 363 | Evaluación de coste-efectividad mediante análisis teórico de minimización de costes del uso de dos mesalazinas gastrorresistentes de liberación prolongada en el manejo de la colitis ulcerosa en España | 0.5 | 2 | Citations (PDF) |
| 364 | Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation | 2.1 | 50 | Citations (PDF) |
| 365 | European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers | 0.0 | 12 | Citations (PDF) |
| 366 | European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian Centers | 0.2 | 1 | Citations (PDF) |
| 367 | Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease | 0.7 | 1 | Citations (PDF) |
| 368 | Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension | 2.1 | 60 | Citations (PDF) |
| 369 | Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second‐line regimen in the presence of levofloxacin resistance – authors' reply | 3.7 | 1 | Citations (PDF) |
| 370 | Letter: clarithromycin dose for H. pylori therapy remains unresolved | 3.7 | 1 | Citations (PDF) |
| 371 | Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm | 3.7 | 1 | Citations (PDF) |
| 372 | Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease – authors' reply | 3.7 | 2 | Citations (PDF) |
| 373 | Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy | 3.7 | 116 | Citations (PDF) |
| 374 | Rectal hypersensitivity in patients with quiescent ulcerative colitis | 1.3 | 10 | Citations (PDF) |
| 375 | Treatment of Helicobacter pylori Infection 2015 | 3.8 | 34 | Citations (PDF) |
| 376 | Identification of Risk Loci for Crohn’s Disease Phenotypes Using a Genome-Wide Association Study | 0.9 | 49 | Citations (PDF) |
| 377 | Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments | 2.5 | 24 | Citations (PDF) |
| 378 | Optimised empiric triple and concomitant therapy forHelicobacter pylorieradication in clinical practice: the OPTRICON study | 3.7 | 83 | Citations (PDF) |
| 379 | Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? | 1.7 | 24 | Citations (PDF) |
| 380 | Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed | 3.7 | 303 | Citations (PDF) |
| 381 | European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases | 1.3 | 556 | Citations (PDF) |
| 382 | Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment forHelicobacter pyloriinfection | 3.1 | 132 | Citations (PDF) |
| 383 | Vedolizumab en el tratamiento de la enfermedad de Crohn | 0.5 | 22 | Citations (PDF) |
| 384 | Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments | 3.7 | 100 | Citations (PDF) |
| 385 | Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy | 2.3 | 70 | Citations (PDF) |
| 386 | Response to | 1.3 | 1 | Citations (PDF) |
| 387 | Response to | 1.3 | 2 | Citations (PDF) |
| 388 | Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry | 1.3 | 49 | Citations (PDF) |
| 389 | Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis | 2.1 | 31 | Citations (PDF) |
| 390 | The association between Helicobacter pylori infection and inflammatory bowel disease based on meta‐analysis | 4.8 | 93 | Citations (PDF) |
| 391 | Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease | 3.7 | 1 | Citations (PDF) |
| 392 | Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. Authors' reply | 3.7 | 0 | Citations (PDF) |
| 393 | Incidencia a los 2 años de nuevas enfermedades inflamatorias mediadas por inmunidad en la cohorte de pacientes con enfermedad inflamatoria intestinal del estudio AQUILES | 0.5 | 10 | Citations (PDF) |
| 394 | Evaluation of the concordance between biological markers and clinical activity in inflammatory bowel disease | 0.1 | 0 | Citations (PDF) |
| 395 | Enfermedades relacionadas con la infección por Helicobacter pylori | 0.5 | 7 | Citations (PDF) |
| 396 | Recomendaciones del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de metotrexato en la enfermedad inflamatoria intestinal | 0.5 | 19 | Citations (PDF) |
| 397 | Concordancia entre la actividad clínica y los marcadores biológicos en la enfermedad inflamatoria intestinal | 0.8 | 5 | Citations (PDF) |
| 398 | Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis | 6.0 | 373 | Citations (PDF) |
| 399 | The potential usefulness of human leukocyte antigen typing for celiac disease screening: A systematic review and meta-analysis | 0.3 | 11 | Citations (PDF) |
| 400 | Response to Letter: Folate deficiency in Crohn's disease | 1.7 | 8 | Citations (PDF) |
| 401 | Systematic review with meta‐analysis: the declining risk of colorectal cancer in ulcerative colitis | 3.7 | 249 | Citations (PDF) |
| 402 | Letter: acute severe ulcerative colitis - should all patients be treated equally? | 3.7 | 1 | Citations (PDF) |
| 403 | Systematic review with meta‐analysis: inflammatory bowel disease in the elderly | 3.7 | 151 | Citations (PDF) |
| 404 | The Effects of Infliximab or Adalimumab on Vascular Endothelial Growth Factor and Angiopoietin 1 Angiogenic Factor Levels in Inflammatory Bowel Disease | 2.9 | 21 | Citations (PDF) |
| 405 | Accuracy of GastroPanel for the diagnosis of atrophic gastritis | 1.3 | 61 | Citations (PDF) |
| 406 | Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units | 1.3 | 103 | Citations (PDF) |
| 407 | P047 Involvement of PSGL1 and its ligands P-, E- and L-selectins in inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 408 | P490 Evolution of the first-line biologic treatment and cost derived from biologic therapy from year 2000: Results of the Biologic Therapies Unit (BTU) at Hospital Universitario de La Princesa | 1.3 | 0 | Citations (PDF) |
| 409 | Risk of colectomy in patients with ulcerative colitis under thiopurine treatment | 1.3 | 28 | Citations (PDF) |
| 410 | P080 Effect of chondroitin sulphate on pro-inflammatory mediators and disease activity in patients with inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 411 | Randomised clinical trial comparing sequential and concomitant therapies for
Helicobacter pylori
eradication in routine clinical practice | 16.8 | 130 | Citations (PDF) |
| 412 | Sa1265 Meta-Analysis on the Efficacy of a Second-Line Anti-TNF in Inflammatory Bowel Disease Patients With Failure to a Previous Anti-TNF Treatment | 0.9 | 1 | Citations (PDF) |
| 413 | Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab | 1.0 | 57 | Citations (PDF) |
| 414 | Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3) | 1.3 | 54 | Citations (PDF) |
| 415 | Enfermedades relacionadas con la infección por Helicobacter pylori | 0.5 | 1 | Citations (PDF) |
| 416 | How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? | 2.6 | 13 | Citations (PDF) |
| 417 | A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis | 2.9 | 44 | Citations (PDF) |
| 418 | Últimas novedades presentadas en gastroenterología | 0.5 | 0 | Citations (PDF) |
| 419 | Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio Aquiles | 0.5 | 10 | Citations (PDF) |
| 420 | P287 Accuracy of fecal calprotectin in the prediction of endoscopic activity in inflammatory bowel disease patients | 1.3 | 0 | Citations (PDF) |
| 421 | Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review | 1.3 | 33 | Citations (PDF) |
| 422 | Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database | 1.3 | 22 | Citations (PDF) |
| 423 | P213 High prevalence of subclinical ultrasonographic synovitis in patients with inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 424 | Su1165 Meta-Analysis of Sequential vs. Standard Triple Therapy for Helicobacter pylori Eradication: Final Results of a Cochrane Systematic Review | 0.9 | 3 | Citations (PDF) |
| 425 | P007 The ratio of circulating estrogen receptors beta and alpha (ER?/ERa) indicates endoscopic activity in patients with Crohn's disease | 1.3 | 0 | Citations (PDF) |
| 426 | Su1171 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple “Sequential” or “Concomitant” Treatment to Eradicate H. pylori Infection | 0.9 | 5 | Citations (PDF) |
| 427 | P508 Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice | 1.3 | 1 | Citations (PDF) |
| 428 | P014 The effect of the anti-TNFα adalimumab on the levels of angiogenic factors in mucosal cultures from patients with inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 429 | Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers | 2.1 | 91 | Citations (PDF) |
| 430 | Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy | 2.1 | 49 | Citations (PDF) |
| 431 | Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España | 0.0 | 6 | Citations (PDF) |
| 432 | Enfermedades relacionadas con la infección por Helicobacter pylori | 0.5 | 9 | Citations (PDF) |
| 433 | Últimas novedades presentadas en gastroenterología | 0.5 | 0 | Citations (PDF) |
| 434 | P494 High dose intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement | 1.3 | 0 | Citations (PDF) |
| 435 | Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance | 0.9 | 190 | Citations (PDF) |
| 436 | Health Care Costs of Complex Perianal Fistula in Crohn’s Disease | 2.1 | 43 | Citations (PDF) |
| 437 | Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical GuideDrugs, 2013, 73, 1761-1770 | 11.4 | 36 | Citations (PDF) |
| 438 | Treatment of Helicobacter pylori Infection 2013 | 3.8 | 54 | Citations (PDF) |
| 439 | Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy | 5.3 | 20 | Citations (PDF) |
| 440 | Letter: mucosal healing in ulcerative colitis – higher relevance than in Crohn's disease? | 3.7 | 1 | Citations (PDF) |
| 441 | Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided | 3.7 | 1 | Citations (PDF) |
| 442 | Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents | 2.3 | 13 | Citations (PDF) |
| 443 | Sa1916 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple “Sequential” or “Concomitant” Treatment to Eradicate H. pylori Infection | 0.9 | 1 | Citations (PDF) |
| 444 | Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013) | 0.5 | 34 | Citations (PDF) |
| 445 | Sa1912 When Standard Triple Therapy With PPI+Amoxicillin+Clarithromycin Fails in the Eradication of Helicobacter pylori, What's Next? | 0.9 | 2 | Citations (PDF) |
| 446 | Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1 | 3.2 | 13 | Citations (PDF) |
| 447 | P507 Evolution of osteopenia and osteoporosis over 5 years in patients with inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 448 | Actualización de la eficacia de la terapia triple para la infección por Helicobacter pylori y de la resistencia a claritromicina en España (2007-2012) | 0.5 | 42 | Citations (PDF) |
| 449 | The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology | 0.5 | 2 | Citations (PDF) |
| 450 | Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease | 1.3 | 30 | Citations (PDF) |
| 451 | P081 Effect of condroitin sulphate on pro-inflammatory mediators and disease activity in patients with inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 452 | Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome | 1.3 | 81 | Citations (PDF) |
| 453 | Guía clínica GETECCU del tratamiento de la colitis ulcerosa elaborada con la metodología GRADE | 0.5 | 25 | Citations (PDF) |
| 454 | Therapeutic guidelines on ulcerative colitis: A GRADE methodology based effort of GETECCU | 0.5 | 45 | Citations (PDF) |
| 455 | P059 Immunohistochemical expression of angiopoietin 1 (Ang1), CD34 and D2.40 in colon of patients with inflammatory bowel disease (IBD) and its association with endoscopic activity | 1.3 | 0 | Citations (PDF) |
| 456 | Reply to Dr. Katsanos et al.'s letter | 1.3 | 0 | Citations (PDF) |
| 457 | P080 Effect of insulin like growth factor-1 on experimental colitis | 1.3 | 0 | Citations (PDF) |
| 458 | P034 Serum concentration of estrogen is associated with inflammatory bowel disease activity | 1.3 | 0 | Citations (PDF) |
| 459 | III Conferencia Española de Consenso sobre la infección por Helicobacter pylori | 0.5 | 72 | Citations (PDF) |
| 460 | Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report and a short review of the literature | 1.3 | 4 | Citations (PDF) |
| 461 | Prevalencia y características de la anemia y ferropenia en pacientes hospitalizados por enfermedades digestivas en España. | 0.5 | 11 | Citations (PDF) |
| 462 | Vaccination strategies in patients with IBD | 45.8 | 29 | Citations (PDF) |
| 463 | Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease | 0.7 | 214 | Citations (PDF) |
| 464 | Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence | 4.3 | 107 | Citations (PDF) |
| 465 | Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease | 0.7 | 110 | Citations (PDF) |
| 466 | Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicateH. pyloriinfection | 1.7 | 35 | Citations (PDF) |
| 467 | Intravenous iron in inflammatory bowel diseases | 2.0 | 26 | Citations (PDF) |
| 468 | Letter: infliximab in severe ulcerative colitis – is it useful for all patients? | 3.7 | 1 | Citations (PDF) |
| 469 | Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era | 3.7 | 80 | Citations (PDF) |
| 470 | Helicobacter Pylori “Test-and-Treat” Strategy for Management of Dyspepsia: A Comprehensive Review | 2.7 | 69 | Citations (PDF) |
| 471 | Response to Tung et al. | 0.7 | 0 | Citations (PDF) |
| 472 | Kinetics of Anti–Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease | 2.9 | 43 | Citations (PDF) |
| 473 | Safety of Thiopurine Therapy in Inflammatory Bowel Disease | 2.9 | 286 | Citations (PDF) |
| 474 | Impact of Current Smoking on the Clinical Course of Microscopic Colitis | 2.9 | 59 | Citations (PDF) |
| 475 | Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection | 2.3 | 64 | Citations (PDF) |
| 476 | Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection | 2.1 | 51 | Citations (PDF) |
| 477 | Probiotics for Helicobacter pylori eradication therapy: not ready for prime time | 0.3 | 16 | Citations (PDF) |
| 478 | Linfoma gástrico MALT | 0.3 | 1 | Citations (PDF) |
| 479 | Potent Gastric Acid Inhibition in Helicobacter pylori Eradication | 11.4 | 13 | Citations (PDF) |
| 480 | Rescue Therapy forHelicobacter pyloriInfection 2012 | 2.5 | 35 | Citations (PDF) |
| 481 | Treatment of Helicobacter pylori infection 2012 | 3.8 | 37 | Citations (PDF) |
| 482 | Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis – authors' reply | 3.7 | 0 | Citations (PDF) |
| 483 | Letter: are lymphocytic colitis and collagenous colitis really the same disease? | 3.7 | 9 | Citations (PDF) |
| 484 | Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains | 3.8 | 85 | Citations (PDF) |
| 485 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial | 62.1 | 603 | Citations (PDF) |
| 486 | Últimas novedades presentadas en gastroenterología | 0.5 | 0 | Citations (PDF) |
| 487 | Su1681 Meta-Analysis of Studies Comparing the First and New Generation Proton Pump Inhibitors in the Eradication of Helicobacter pylori | 0.9 | 1 | Citations (PDF) |
| 488 | Su1694 Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of Helicobacter pylori | 0.9 | 2 | Citations (PDF) |
| 489 | Su1689 Helicobacter pylori Infection in Spain: Is Its Prevalence Really Decreasing? | 0.9 | 1 | Citations (PDF) |
| 490 | Su1690 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Quadruple Non-Bismuth “Sequential” or “Concomitant” Treatment | 0.9 | 1 | Citations (PDF) |
| 491 | Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding | 0.7 | 70 | Citations (PDF) |
| 492 | Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease | 3.7 | 109 | Citations (PDF) |
| 493 | Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease | 0.7 | 137 | Citations (PDF) |
| 494 | P028 Immunohistochemical expression of Angiopoietin 1 (Ang1) and microvessels density in colon of patients with inflammatory bowel disease (IBD) | 1.3 | 2 | Citations (PDF) |
| 495 | P040 Relationship between levels of angiogenic and lymphangiogenic factors (ALF) and the extension, endoscopic activity, and acute phase reactants (APR) in patients with Crohn's disease (CD) | 1.3 | 0 | Citations (PDF) |
| 496 | P050 Relationship between levels of angiogenic and lymphangiogenic factors (ALF) and the extension, endoscopic activity, and acute phase reactants (APR) in patients with ulcerative colitis (UC) | 1.3 | 2 | Citations (PDF) |
| 497 | P051 Relationship between histological activity of inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors (ALF) | 1.3 | 2 | Citations (PDF) |
| 498 | P080 Desensitization of the IGF-1 receptor signal transduction in rat colon with experimental colitis | 1.3 | 0 | Citations (PDF) |
| 499 | P103 Correlation between serological biomarkers and clinical activity in patients with inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 500 | P104 Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease (IBD) | 1.3 | 0 | Citations (PDF) |
| 501 | P112 The natural history of Crohn's disease (CD): A long-term (>10 years) follow-up study | 1.3 | 0 | Citations (PDF) |
| 502 | P122 The natural history of Crohn's disease: Impact of the introduction of thiopurines on its outcome | 1.3 | 0 | Citations (PDF) |
| 503 | P231 Efficacy of hepatitis B vaccination and re-vaccination and factors impacting on the response in inflammatory bowel disease patients | 1.3 | 0 | Citations (PDF) |
| 504 | P318 Kinetics of the anti-HBs titers after vaccination against hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD) | 1.3 | 1 | Citations (PDF) |
| 505 | Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012 | 0.8 | 8 | Citations (PDF) |
| 506 | Manejo del paciente con dispepsia. Guía de práctica clínica. Actualización 2012. Resumen ejecutivo | 0.8 | 11 | Citations (PDF) |
| 507 | Intensification of infliximab therapy in Crohn's disease: Efficacy and safety | 1.3 | 38 | Citations (PDF) |
| 508 | Genital fistulas in female Crohn's disease patients. | 1.3 | 40 | Citations (PDF) |
| 509 | Adherence of gastroenterologists to European Crohn's and Colitis Organisation Consensus on Crohn's disease: A real-life survey in Spain | 1.3 | 14 | Citations (PDF) |
| 510 | Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease | 1.3 | 14 | Citations (PDF) |
| 511 | Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease | 1.3 | 37 | Citations (PDF) |
| 512 | Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012 | 0.5 | 14 | Citations (PDF) |
| 513 | Enfermedades relacionadas con la infección por Helicobacter pylori | 0.5 | 8 | Citations (PDF) |
| 514 | Su1685 Maintenance of Helicobacter pylori Eradication Rates With Triple Therapy Over 12 Years in a Spanish Hospital | 0.9 | 1 | Citations (PDF) |
| 515 | Su1708 Photodynamic Therapy: an Alternative Strategy Against Helicobacter pylori | 0.9 | 1 | Citations (PDF) |
| 516 | Management of
Helicobacter pylori
infection—the Maastricht IV/ Florence Consensus Report | 16.8 | 2,176 | Citations (PDF) |
| 517 | Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori | 2.8 | 122 | Citations (PDF) |
| 518 | Long-term durability of response to adalimumab in Crohnʼs disease | 2.9 | 53 | Citations (PDF) |
| 519 | Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response | 2.9 | 127 | Citations (PDF) |
| 520 | Accuracy of Urea Breath Test Performed Immediately After Emergency Endoscopy in Peptic Ulcer Bleeding | 2.1 | 17 | Citations (PDF) |
| 521 | Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study | 3.7 | 109 | Citations (PDF) |
| 522 | Review article: rifabutin in the treatment of refractoryHelicobacter pyloriinfection | 3.7 | 180 | Citations (PDF) |
| 523 | Fourth‐line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures | 3.7 | 59 | Citations (PDF) |
| 524 | Validation of a Genotyping Method for Analysis of TPMT Polymorphisms | 2.7 | 10 | Citations (PDF) |
| 525 | Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease | 3.7 | 89 | Citations (PDF) |
| 526 | Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection | 3.7 | 27 | Citations (PDF) |
| 527 | High‐dose, ten‐day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates | 3.7 | 28 | Citations (PDF) |
| 528 | Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of
H
elicobacter pylori
infection | 3.7 | 185 | Citations (PDF) |
| 529 | Papel de los fármacos tiopurínicos en la colitis ulcerosa | 0.5 | 0 | Citations (PDF) |
| 530 | Empirical Rescue Eradication Regimen for H. pylori Infection Following Two Treatment Failures: A Systematic Review and Meta-Analysis | 0.9 | 1 | Citations (PDF) |
| 531 | Meta-Analysis: Rabeprazole and Esomeprazole in the Eradication of Helicobacter pylori | 0.9 | 2 | Citations (PDF) |
| 532 | Amoxicillin Gastric Retention Systems for Helicobacter pylori Treatment | 0.9 | 3 | Citations (PDF) |
| 533 | Hiperplasia nodular regenerativa: hepatotoxicidad por azatioprina en un paciente con enfermedad de Crohn | 0.5 | 10 | Citations (PDF) |
| 534 | Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori | 0.5 | 20 | Citations (PDF) |
| 535 | Diez noticias relevantes para la práctica clínica en Gastroenterología publicadas en el año 2010 | 0.5 | 0 | Citations (PDF) |
| 536 | Alteraciones del metabolismo óseo en 100 pacientes con enfermedad inflamatoria intestinal | 0.5 | 2 | Citations (PDF) |
| 537 | Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease | 0.5 | 27 | Citations (PDF) |
| 538 | Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience | 0.5 | 27 | Citations (PDF) |
| 539 | Evaluation of liver fibrosis by transient elastography in methotrexate treated patients | 0.8 | 28 | Citations (PDF) |
| 540 | Últimas novedades presentadas en gastroenterología | 0.5 | 0 | Citations (PDF) |
| 541 | Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico | 0.5 | 8 | Citations (PDF) |
| 542 | Soluble Angiogenic Factors in Patients With Acute Pancreatitis | 2.3 | 18 | Citations (PDF) |
| 543 | Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response | 2.3 | 119 | Citations (PDF) |
| 544 | Is Culture Necessary before First-line Treatment for Helicobacter pylori Infection? | 0.8 | 17 | Citations (PDF) |
| 545 | Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab | 3.7 | 95 | Citations (PDF) |
| 546 | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori | 3.7 | 165 | Citations (PDF) |
| 547 | Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma | 3.7 | 61 | Citations (PDF) |
| 548 | Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough | 3.7 | 124 | Citations (PDF) |
| 549 | Consumo de recursos sanitarios y pérdida de productividad en la enfermedad por reflujo gastroesofágico: resultados de un estudio transversal en el ámbito de la atención primaria en España | 0.8 | 3 | Citations (PDF) |
| 550 | Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease | 3.7 | 108 | Citations (PDF) |
| 551 | Últimas novedades presentadas en gastroenterología | 0.5 | 2 | Citations (PDF) |
| 552 | Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico | 0.5 | 7 | Citations (PDF) |
| 553 | Successful use of infliximab for perianal Crohnʼs disease in pregnancy | 2.9 | 9 | Citations (PDF) |
| 554 | Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease | 2.9 | 34 | Citations (PDF) |
| 555 | Has H. pylori Prevalence in Bleeding Peptic Ulcer Been Underestimated? A Meta-Regression | 0.7 | 76 | Citations (PDF) |
| 556 | Levofloxacin in first-line eradication regimens for
Helicobacter pylori
: better test antibiotic susceptibility before treatingGut, 2011, 60, 1605.1-1605 | 16.8 | 9 | Citations (PDF) |
| 557 | In Response: | 2.3 | 31 | Citations (PDF) |
| 558 | Sequential Therapy for Helicobacter pylori Eradication | 2.3 | 202 | Citations (PDF) |
| 559 | Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer | 2.8 | 12 | Citations (PDF) |
| 560 | Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding | 2.9 | 125 | Citations (PDF) |
| 561 | Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies | 2.4 | 6 | Citations (PDF) |
| 562 | Intravenous iron in digestive diseases: a clinical (re)view | 2.4 | 11 | Citations (PDF) |
| 563 | W1300 Effectiveness of Infliximab After Adalimumab Failure in Crohn's Disease | 0.9 | 2 | Citations (PDF) |
| 564 | M1697 Effect of Helicobacter pylori Eradication on Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Randomized Clinical Trials | 0.9 | 2 | Citations (PDF) |
| 565 | M1698 Helicobacter pylori and Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Case-Control Studies | 0.9 | 1 | Citations (PDF) |
| 566 | M1136 Helicobacter pylori Levofloxacin-Based Rescue Option in Patients Allergic to Penicillin Failing a Previous Treatment With Clarithromycin and Metronidazole | 0.9 | 1 | Citations (PDF) |
| 567 | M1115 Sequential Therapy for Helicobacter pylori Eradication: A Critical Review | 0.9 | 3 | Citations (PDF) |
| 568 | M1113 Clarithromycin or Levofloxacin in First-Line Triple and Sequential Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial | 0.9 | 2 | Citations (PDF) |
| 569 | Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? | 1.3 | 144 | Citations (PDF) |
| 570 | Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain | 1.3 | 33 | Citations (PDF) |
| 571 | Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin | 2.5 | 58 | Citations (PDF) |
| 572 | Primer consenso español sobre el tratamiento de la hemorragia digestiva por úlcera péptica | 0.8 | 22 | Citations (PDF) |
| 573 | ¿Es necesario asociar inmunomoduladores al tratamiento biológico en la enfermedad inflamatoria intestinal? | 0.5 | 4 | Citations (PDF) |
| 574 | Estudio de síntomas relevantes y atención clínica en la enfermedad por reflujo gastroesofágico en atención primaria en España | 0.5 | 2 | Citations (PDF) |
| 575 | Colaboración científica y ámbitos de investigación en Gastroenterología y Hepatología y Revista Española de Enfermedades Digestivas (2000–2009) | 0.5 | 9 | Citations (PDF) |
| 576 | Treatment of Helicobacter pylori infection: The past and the future | 2.7 | 31 | Citations (PDF) |
| 577 | Corticosteroids Modulate Angiogenic Soluble Factors in Ulcerative Colitis Patients | 2.1 | 10 | Citations (PDF) |
| 578 | Loss of Response and Requirement of Infliximab Dose Intensification in Crohnʼs Disease | 0.7 | 0 | Citations (PDF) |
| 579 | Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study | 1.7 | 10 | Citations (PDF) |
| 580 | Response to Chao and Mulani | 0.7 | 1 | Citations (PDF) |
| 581 | Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease | 2.9 | 105 | Citations (PDF) |
| 582 | Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement | 2.9 | 134 | Citations (PDF) |
| 583 | Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse | 2.9 | 288 | Citations (PDF) |
| 584 | H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study | 1.5 | 5 | Citations (PDF) |
| 585 | Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis | 3.7 | 200 | Citations (PDF) |
| 586 | Review article: Helicobacter pylori‐negative duodenal ulcer disease | 3.7 | 114 | Citations (PDF) |
| 587 | Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain | 3.0 | 46 | Citations (PDF) |
| 588 | What Is the Best Strategy for Diagnosis and Treatment of Helicobacter pylori in the Prevention of Recurrent Peptic Ulcer Bleeding? A Cost-Effectiveness Analysis | 1.9 | 10 | Citations (PDF) |
| 589 | Publicación científica, indicadores bibliométricos e índice h de Hirsch | 0.5 | 23 | Citations (PDF) |
| 590 | Papel de Mycobacterium avium paratuberculosis en la etiopatogenia de la enfermedad de Crohn | 0.5 | 3 | Citations (PDF) |
| 591 | Prevalencia y características de la anemia en la enfermedad inflamatoria intestinal | 0.5 | 5 | Citations (PDF) |
| 592 | Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease | 2.5 | 216 | Citations (PDF) |
| 593 | P025 - Patient preferences for Crohn's disease maintenance therapy: a discrete choice experiment | 1.3 | 1 | Citations (PDF) |
| 594 | P078 - Patient preferences for Crohn's disease flare-up therapy: a discrete choice experiment | 1.3 | 0 | Citations (PDF) |
| 595 | P119 - Efficacy of azathioprine and mercaptopurine in ulcerative colitis. Systematic review and meta-analysis | 1.3 | 0 | Citations (PDF) |
| 596 | P157 - Intensification of infliximab (IFX) therapy in Crohn's disease: efficacy and safety | 1.3 | 0 | Citations (PDF) |
| 597 | P174 - How often does infliximab lose its effect and dose intensification is required? A review | 1.3 | 0 | Citations (PDF) |
| 598 | P310 - The effect of infliximab treatment on angiogenic factors levels in patients with inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 599 | Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting | 2.9 | 45 | Citations (PDF) |
| 600 | Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study | 2.9 | 66 | Citations (PDF) |
| 601 | Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review | 0.7 | 595 | Citations (PDF) |
| 602 | Management of gastro-oesophageal reflux disease in primary care: a European observational study | 2.1 | 17 | Citations (PDF) |
| 603 | M1065 Third-Line Levofloxacin-Based Rescue Regimen in Patients with Two H. pylori Eradication Failures: A Spanish Multicenter Study | 0.9 | 1 | Citations (PDF) |
| 604 | Review: Second-line rescue therapy of Helicobacter pylori infection | 3.2 | 26 | Citations (PDF) |
| 605 | Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for Helicobacter pylori Eradication | 2.3 | 19 | Citations (PDF) |
| 606 | Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study | 1.7 | 12 | Citations (PDF) |
| 607 | Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients | 3.7 | 78 | Citations (PDF) |
| 608 | Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohnʼs disease patients | 2.9 | 39 | Citations (PDF) |
| 609 | Meta‐analysis: high‐dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication | 3.7 | 126 | Citations (PDF) |
| 610 | ¿Cómo localizar, elaborar, evaluar y utilizar guías de práctica clínica? | 0.5 | 15 | Citations (PDF) |
| 611 | Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response | 0.5 | 27 | Citations (PDF) |
| 612 | Aproximación B. En la hemorragia digestiva alta los inhibidores de la bomba de protones por vía intravenosa sólo deben administrarse una vez que la endoscopia haya demostrado estigmas de alto riesgo de resangrado | 0.5 | 1 | Citations (PDF) |
| 613 | Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study | 0.5 | 23 | Citations (PDF) |
| 614 | M1075 Second-Line Rescue Therapy with Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study | 0.9 | 1 | Citations (PDF) |
| 615 | Common Misconceptions in the Diagnosis and Management of Anemia in Inflammatory Bowel Disease | 0.7 | 212 | Citations (PDF) |
| 616 | Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico | 0.5 | 3 | Citations (PDF) |
| 617 | Ten-Day Sequential Treatment forHelicobacter pyloriEradication in Clinical Practice | 0.7 | 67 | Citations (PDF) |
| 618 | M1076 Helicobacter pylori First-Line Treatment and Rescue Option in Patients Allergic to Penicillin | 0.9 | 1 | Citations (PDF) |
| 619 | M1073 Fourth-Line Rescue Therapy in Patients with Three H. pylori Eradication Failures | 0.9 | 1 | Citations (PDF) |
| 620 | M1096 High Dose vs. Standard Dose Proton Pump Inhibitor Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis | 0.9 | 4 | Citations (PDF) |
| 621 | Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients | 0.7 | 79 | Citations (PDF) |
| 622 | Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review | 0.7 | 238 | Citations (PDF) |
| 623 | Dual Versus Endoscopic Monotherapy in Bleeding Peptic Ulcers | 0.7 | 4 | Citations (PDF) |
| 624 | Analysis of soluble angiogenic factors in Crohn’s disease: a preliminary study | 0.5 | 11 | Citations (PDF) |
| 625 | Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review | 0.7 | 196 | Citations (PDF) |
| 626 | Immunological changes at rectal mucosa in appendectomised subjects and inhabitants of developing countries | 0.5 | 0 | Citations (PDF) |
| 627 | Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal | 0.5 | 42 | Citations (PDF) |
| 628 | Errores frecuentes en el manejo del paciente grave con enfermedad inflamatoria intestinal | 0.5 | 5 | Citations (PDF) |
| 629 | Computed tomography colonography compared with conventional colonoscopy for the detection of colorectal polyps | 0.5 | 13 | Citations (PDF) |
| 630 | Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal | 0.5 | 8 | Citations (PDF) |
| 631 | Refractory and Infected Pyoderma Gangrenosum in a Patient With Ulcerative Colitis: Response to Infliximab | 2.9 | 13 | Citations (PDF) |
| 632 | 5-Aminosalicylates and renal function in inflammatory bowel disease | 2.9 | 208 | Citations (PDF) |
| 633 | Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients | 2.9 | 111 | Citations (PDF) |
| 634 | First‐line triple therapy with levofloxacin for Helicobacter pylori eradication | 3.7 | 51 | Citations (PDF) |
| 635 | Eradication of Helicobacter pylori for the Prevention of Peptic Ulcer Rebleeding | 3.8 | 33 | Citations (PDF) |
| 636 | 13C-urea Breath Test during Hospitalization for the Diagnosis of Helicobacter pylori Infection in Peptic Ulcer Bleeding | 3.8 | 29 | Citations (PDF) |
| 637 | Evolution of Helicobacter pylori Therapy from a Meta‐analytical Perspective | 3.8 | 80 | Citations (PDF) |
| 638 | Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients | 2.1 | 84 | Citations (PDF) |
| 639 | Prevalence of Macrocreatinkinase Type 1 in Patients with Inflammatory Bowel Disease | 2.1 | 6 | Citations (PDF) |
| 640 | Prevalencia de la infección por Helicobacter pylori en el linfoma MALT gástrico: una revisión sistemática | 0.3 | 53 | Citations (PDF) |
| 641 | El desarrollo vascular en la enfermedad inflamatoria intestinal | 0.5 | 11 | Citations (PDF) |
| 642 | Tratamiento farmacológico de la hemorragia digestiva por úlcera péptica | 0.8 | 2 | Citations (PDF) |
| 643 | Monitorización de la tiopurina metiltransferasa y de los metabolitos tiopurínicos para optimizar el tratamiento con azatioprina en la enfermedad inflamatoria intestinal | 0.5 | 21 | Citations (PDF) |
| 644 | ¿Siete o diez días? Estudio de coste-efectividad sobre la duración del tratamiento de la infección por H. pylori en atención primaria | 0.8 | 4 | Citations (PDF) |
| 645 | Últimas novedades presentadas en gastroenterología. Introducción | 0.5 | 10 | Citations (PDF) |
| 646 | Enfermedades relacionadas con H. pylori: dispepsia, úlcera y cáncer gástrico | 0.5 | 3 | Citations (PDF) |
| 647 | Is there any correlation between 13C-urea breath test values and response to first-line and rescue Helicobacter pylori eradication therapies? | 2.5 | 11 | Citations (PDF) |
| 648 | Clinical Trial Evaluating Amoxicillin and Clarithromycin Hydrogels (Chitosan-polyacrylic Acid Polyionic Complex) for H. pylori Eradication | 2.3 | 23 | Citations (PDF) |
| 649 | Risk Assessment and Outpatient Management in Bleeding Peptic Ulcer | 2.3 | 13 | Citations (PDF) |
| 650 | Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure | 3.7 | 305 | Citations (PDF) |
| 651 | Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures | 3.7 | 84 | Citations (PDF) |
| 652 | The Role of Tacrolimus in Inflammatory Bowel Disease: A Systematic Review | 2.1 | 39 | Citations (PDF) |
| 653 | Accuracy of Helicobacter pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis | 0.7 | 201 | Citations (PDF) |
| 654 | Accuracy of Monoclonal Stool Antigen Test for the Diagnosis ofH. pyloriInfection: A Systematic Review and Meta-Analysis | 0.7 | 283 | Citations (PDF) |
| 655 | Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures | 0.7 | 101 | Citations (PDF) |
| 656 | Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients | 0.7 | 114 | Citations (PDF) |
| 657 | Gastric MALT lymphoma: clinical characteristics and prevalence of H. pylori infection in a series of 37 cases | 0.3 | 14 | Citations (PDF) |
| 658 | Helicobacter pylori: its discovery and relevance for medicine | 0.3 | 31 | Citations (PDF) |
| 659 | Is the string test a useful alternative to gastroscopy with biopsy for H. pylori identification? | 0.3 | 2 | Citations (PDF) |
| 660 | Helicobacter pylori"Rescue" Therapy After Failure of Two Eradication Treatments | 3.8 | 102 | Citations (PDF) |
| 661 | Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users | 3.7 | 206 | Citations (PDF) |
| 662 | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure | 3.7 | 11 | Citations (PDF) |
| 663 | Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin | 3.7 | 61 | Citations (PDF) |
| 664 | The Recurrence of Helicobacter pylori Infection: Incidence and Variables Influencing It. A Critical Review | 0.7 | 116 | Citations (PDF) |
| 665 | Esomeprazole-Based Therapy in Helicobacter pylori Eradication: Any Effect by Increasing the Dose of Esomeprazole or Prolonging the Treatment? | 0.7 | 34 | Citations (PDF) |
| 666 | Evaluation of 3 different tests for the detection of stool antigens to confirm Helicobacter pylori eradication after treatment. A pilot study | 0.5 | 20 | Citations (PDF) |
| 667 | Indicaciones y consecuencias de la erradicación de Helicobacter pylori en la enfermedad por reflujo gastroesofágico | 0.8 | 5 | Citations (PDF) |
| 668 | Pruebas de aliento en el diagnóstico de enfermedades digestivas | 0.5 | 7 | Citations (PDF) |
| 669 | Actividad de la tiopurina metiltransferasa en la enfermedad inflamatoria intestinal. Un estudio en 7.046 pacientes españoles | 0.8 | 9 | Citations (PDF) |
| 670 | Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso | 0.8 | 53 | Citations (PDF) |
| 671 | Prevención de la recidiva hemorrágica por úlcera péptica mediante la erradicación de Helicobacter pylori | 0.5 | 5 | Citations (PDF) |
| 672 | 13C-urea breath test in the management of Helicobacter pylori infection | 2.5 | 39 | Citations (PDF) |
| 673 | Indications, diagnostic tests and Helicobacter pylori eradication therapy: Recommendations by the 2nd Spanish Consensus Conference | 0.3 | 30 | Citations (PDF) |
| 674 | Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer | 3.7 | 140 | Citations (PDF) |
| 675 | Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding | 3.7 | 41 | Citations (PDF) |
| 676 | Review article: 13 C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review | 3.7 | 341 | Citations (PDF) |
| 677 | The TETRA Study: A prospective evaluation of Helicobacter pylori'Test-and-Treat' Strategy on 736 Patients in Clinical Practice | 3.8 | 35 | Citations (PDF) |
| 678 | Empirical Helicobacter pylori “rescue” therapy after failure of two eradication treatments | 2.5 | 21 | Citations (PDF) |
| 679 | Helicobacter pylori and perforated peptic ulcer. Prevalence of the infection and role of non-steroidal anti-inflammatory drugs | 2.5 | 53 | Citations (PDF) |
| 680 | Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis | 2.5 | 31 | Citations (PDF) |
| 681 | Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer | 2.1 | 72 | Citations (PDF) |
| 682 | Anticuerpos anticitoplasma de los neutrófilos en el diagnóstico de la colitis ulcerosa y la enfermedad de Crohn | 0.8 | 4 | Citations (PDF) |
| 683 | ¿Cómo realizar, evaluar y utilizar revisiones sistemáticas y metaanálisis? | 0.5 | 28 | Citations (PDF) |
| 684 | Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers | 0.9 | 258 | Citations (PDF) |
| 685 | Hepatocellular carcinoma risk in patients with porphyria cutanea tarda | 1.3 | 40 | Citations (PDF) |
| 686 | The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma | 1.3 | 31 | Citations (PDF) |
| 687 | 'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures | 3.8 | 99 | Citations (PDF) |
| 688 | Treatment of helicobacter pylori eradication failures | 0.9 | 7 | Citations (PDF) |
| 689 | Is there an optimal therapeutic regimen for antimitochondrial antibody‐negative primary biliary cirrhosis (autoimmune cholangitis)? | 3.7 | 23 | Citations (PDF) |
| 690 | Rabeprazole-based therapies in Helicobacter pylori eradication | 3.7 | 35 | Citations (PDF) |
| 691 | Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta‐analysis | 3.7 | 77 | Citations (PDF) |
| 692 | Actividad de la tiopurina metiltransferasa y mielotoxicidad debida a azatioprina y 6-mercaptopurina en pacientes con enfermedad inflamatoria del intestino | 0.8 | 9 | Citations (PDF) |
| 693 | Comparación entre dos pruebas del aliento con 13C-urea para el diagnóstico de la infección por Helicobacter pylori: espectrometría de masas frente a infrarrojos | 0.5 | 13 | Citations (PDF) |
| 694 | Ciclooxigenasa 2 (COX-2), Helicobacter pylori y cáncer gástrico | 0.8 | 3 | Citations (PDF) |
| 695 | Actividad de la tiopurina metiltransferasa en pacientes con hepatitis autoinmune | 0.8 | 5 | Citations (PDF) |
| 696 | Papel de los anticuerpos anticitoplasma de los neutrófilos (ANCA) y anti-Saccharomyces cerevisiae (ASCA) en la enfermedad inflamatoria intestinal | 0.5 | 17 | Citations (PDF) |
| 697 | Ciclooxigenasa-2 y lesiones gastroduodenales. ¿Alguna relación con Helicobacter pylori ? | 0.8 | 6 | Citations (PDF) |
| 698 | Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis | 0.9 | 309 | Citations (PDF) |
| 699 | Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis | 4.2 | 149 | Citations (PDF) |
| 700 | Helicobacter pylori and Bleeding Peptic Ulcer: What is the Prevalence of the Infection in Patients with this Complication? | 1.7 | 46 | Citations (PDF) |
| 701 | Ciclooxigenasa 2 (COX-2), Helicobacter pylori y cáncer gástrico | 0.8 | 1 | Citations (PDF) |
| 702 | Actividad de la tiopurina metiltransferasa y mielotoxicidad debida a azatioprina y 6-mercaptopurina en pacientes con enfermedad inflamatoria del intestino | 0.8 | 5 | Citations (PDF) |
| 703 | Ciclooxigenasa-2 y lesiones gastroduodenales. ¿Alguna relación con Helicobacter pylori? | 0.8 | 1 | Citations (PDF) |
| 704 | Actividad de la tiopurina metiltransferasa en pacientes con hepatitis autoinmune | 0.8 | 1 | Citations (PDF) |
| 705 | Role of partner's infection in reinfection after Helicobacter pylori eradication | 1.3 | 43 | Citations (PDF) |
| 706 | The Stool Antigen Test for Detection of Helicobacter pylori after Eradication Therapy | 9.6 | 112 | Citations (PDF) |
| 707 | Serología «rápida» para el diagnóstico de la infección por Helicobacter pylori, ¿puede recomendarse su empleo sistemático en la práctica clínica? | 0.8 | 4 | Citations (PDF) |
| 708 | Anticuerpos frente a la citotoxina CagA de Helicobacter pylori en diversas enfermedades gastroduodenales en dos poblaciones diferentes | 0.8 | 4 | Citations (PDF) |
| 709 | Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT) | 0.1 | 23 | Citations (PDF) |
| 710 | Infección por helicobacter pylori y dispepsia funcional. metaanálisis de la eficacia del tratamiento erradicador | 0.8 | 21 | Citations (PDF) |
| 711 | Detección del antígeno de helicobacter pylori en heces para el diagnóstico inicial de la infección y para la confirmación de su erradicación tras el tratamiento | 0.8 | 15 | Citations (PDF) |
| 712 | Tratamiento de la hepatitis alcohólica con glucocorticoides. ¿Son realmente efectivos? | 0.8 | 0 | Citations (PDF) |
| 713 | Estudio de los factores pronósticos clínicos y endoscópicos en los pacientes con hemorragia digestiva de origen gastroduodenal | 0.8 | 4 | Citations (PDF) |
| 714 | Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal | 0.5 | 37 | Citations (PDF) |
| 715 | Prevalencia de infección por Helicobacter pylori en la hepatopatía crónica y relación con sus complicaciones: revisión sistemática y metaanálisis | 0.8 | 5 | Citations (PDF) |
| 716 | Estudio de la validez de la serología «rápida» para el diagnóstico de la infección por Helicobacter pylori | 0.8 | 4 | Citations (PDF) |
| 717 | Prevalencia de la infección por Helicobacter pylori en la enfermedad por reflujo gastroesofágico y en el esófago de Barrett: revisión sistemática y metaanálisis | 0.8 | 14 | Citations (PDF) |
| 718 | Tratamiento de la enfermedad de Crohn estenosante | 0.5 | 5 | Citations (PDF) |
| 719 | Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta‐analysis | 3.7 | 116 | Citations (PDF) |
| 720 | Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor‐based triple therapies fail | 3.7 | 191 | Citations (PDF) |
| 721 | Title is missing! | 2.1 | 104 | Citations (PDF) |
| 722 | Hemorragia digestiva por úlcera péptica. ¿Se puede estimar con fiabilidad suficiente su pronóstico y evitar el ingreso de algunos pacientes? | 0.8 | 6 | Citations (PDF) |
| 723 | ¿Está indicado erradicar la infección por Helicobacter pylori en los pacientes que requieren tratamiento a largo plazo con inhibidores de la bomba de protones? | 0.8 | 1 | Citations (PDF) |
| 724 | Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática | 0.8 | 32 | Citations (PDF) |
| 725 | Concentraciones basales de gastrina y pepsinógeno I y II en la úlcera gástrica: influencia de la infección por Helicobacter pylori y utilidad en el control de la erradicación | 0.5 | 7 | Citations (PDF) |
| 726 | Helicobacter pylori and Gastroesophageal Reflux Disease | 2.3 | 29 | Citations (PDF) |
| 727 | Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia | 1.3 | 82 | Citations (PDF) |
| 728 | High Efficacy of Ranitidine Bismuth Citrate, Amoxicillin, Clarithromycin and Metronidazole Twice Daily for Only Five Days in Helicobacter pylori Eradication | 3.8 | 15 | Citations (PDF) |
| 729 | Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review | 0.7 | 120 | Citations (PDF) |
| 730 | Helicobacter pylori and Bleeding Duodenal Ulcer: Prevalence of the Infection and Role of Non-steroidal Anti-inflammatory Drugs | 1.7 | 47 | Citations (PDF) |
| 731 | Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review | 0.7 | 2 | Citations (PDF) |
| 732 | One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication | 1.3 | 19 | Citations (PDF) |
| 733 | 13C-urea breath test for the diagnosis of Helicobacter pylori infection | 1.3 | 11 | Citations (PDF) |
| 734 | Helicobacter pylori infection, gastric metaplasia in the duodenum and the relationship with ulcer recurrence | 1.3 | 17 | Citations (PDF) |
| 735 | Concordance Between Noninvasive Tests in Detecting Helicobacter pylori and Potential Use of Serology for Monitoring Eradication in Gastric Ulcer | 2.3 | 12 | Citations (PDF) |
| 736 | A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection | 3.7 | 215 | Citations (PDF) |
| 737 | Helicobacter pylori
eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy | 3.7 | 47 | Citations (PDF) |
| 738 | Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori | 3.7 | 163 | Citations (PDF) |
| 739 | Helicobacter pylori“Test-and-Scope” Strategy for Dyspeptic Patients | 3.8 | 12 | Citations (PDF) |
| 740 | Value of Quantitative Serology for Confirmation of Helicobacter pylori Eradication: An 18-Month Follow-Up Study | 5.2 | 13 | Citations (PDF) |
| 741 | Efecto de la erradicación de Helicobacter pylori sobre las lesiones histológicas de la mucosa gástrica a lo largo de 18 meses | 0.1 | 8 | Citations (PDF) |
| 742 | Diagnóstico de la infección por Helicobacter pylori | 0.1 | 6 | Citations (PDF) |
| 743 | Anticuerpos frente a Helicobacter pylori en saliva. Estudio de su validez frente a la prueba del aliento y de su concordancia con la serología | 0.8 | 6 | Citations (PDF) |
| 744 | Acalasia esofágica. Revisión de sus aspectos clínicos, diagnósticos y terapéuticos | 0.1 | 1 | Citations (PDF) |
| 745 | Efecto de la erradicación de Helicobacter pylori sobre la recurrencia de la úlcera gástrica a lo largo de 12 meses | 0.8 | 2 | Citations (PDF) |
| 746 | Eficacia de cuatro técnicas de amplio uso para el diagnóstico de la infección por Helicobacter pylori en la enfermedad ulcerosa gástrica | 0.1 | 5 | Citations (PDF) |
| 747 | 13C-Phenylalanine and 13C-Methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease | 2.5 | 55 | Citations (PDF) |
| 748 | Seven‐day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole | 3.7 | 79 | Citations (PDF) |
| 749 | Title is missing! | 2.1 | 78 | Citations (PDF) |
| 750 | Helicobacter pylori'Test-and-Treat' Strategy for Dyspeptic Patients | 1.7 | 26 | Citations (PDF) |
| 751 | Prevalence of Helicobacter pylori infection in medical professionals in Spain | 1.3 | 22 | Citations (PDF) |
| 752 | Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori | 1.3 | 23 | Citations (PDF) |
| 753 | Re-treatment after Helicobacter pylon eradication failure | 1.3 | 47 | Citations (PDF) |
| 754 | Mutations in 23S rRNA in
Helicobacter pylori
Conferring Resistance to Erythromycin Do Not Always Confer Resistance to Clarithromycin | 4.1 | 32 | Citations (PDF) |
| 755 | Recurrence ofHelicobacter pyloriInfection after Eradication: Incidence and Variables Influencing It | 1.7 | 52 | Citations (PDF) |
| 756 | Relation between Histologic Subtypes and Location of Gastric Cancer andHelicobacter pylori | 1.7 | 43 | Citations (PDF) |
| 757 | Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics | 1.3 | 21 | Citations (PDF) |
| 758 | Unhealed Duodenal Ulcers despite Helicobacter pylori Eradication | 1.7 | 28 | Citations (PDF) |
| 759 | Verification of Decreased Basal and Stimulated Serum Pepsinogen-I Levels Is a Useful Non-Invasive Method for Determining the Success of Eradication Therapy forHelicobacter pylori | 1.7 | 18 | Citations (PDF) |
| 760 | Basal and Stimulated Gastrin Levels and Gastric Acid Output Five Months After Therapy for Helicobacter Pylori Eradication in Duodenal Ulcer Patients | 2.3 | 25 | Citations (PDF) |
| 761 | Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in patients with portal hypertension | 2.1 | 2 | Citations (PDF) |
| 762 | Optimum duration of regimens for Helicobacter pylori eradication | 2.1 | 138 | Citations (PDF) |
| 763 | Optimum second-line regimens for <i>Helicobacter pylori</i>
eradication | 2.1 | 1 | Citations (PDF) |
| 764 | Title is missing! 0 | | 1 | Citations (PDF) |
| 765 | Empiric use of standard triple therapy in Helicobacter pylori eradication does not require readjustment in the clarithromycin resistance cut-off point | 16.8 | 7 | Citations (PDF) |
| 766 | Effectiveness and Safety of First‐Line Non‐Bismuth Quadruple Concomitant Therapy Versus Single‐Capsule Bismuth Quadruple Therapy | 3.7 | 6 | Citations (PDF) |
| 767 | Helicobacter pylori
antibiotic resistance: a global challenge in search of solutions | 16.8 | 52 | Citations (PDF) |
| 768 | Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The
RAINBOW
‐
IBD
Study of
ENEIDA | 3.7 | 4 | Citations (PDF) |
| 769 | Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review | 1.3 | 13 | Citations (PDF) |
| 770 | Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers | 1.3 | 1 | Citations (PDF) |
| 771 | International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements | 4.8 | 3 | Citations (PDF) |
| 772 | Empirical Rescue Eradication Therapy for
Helicobacter pylori
Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on
H. pylori
Management (Hp‐
BrazilReg
) | 3.8 | 1 | Citations (PDF) |
| 773 | Second‐ and Third‐Line Therapies for
<i>Helicobacter pylori</i>
Eradication in Slovenia: Data From 2013–2023 of the European Registry on
<i>H. pylori</i>
Management | 3.8 | 0 | Citations (PDF) |
| 774 | Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice | 2.9 | 0 | Citations (PDF) |
| 775 | Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry | 4.8 | 1 | Citations (PDF) |
| 776 | Successful eradication of multidrug-resistant Helicobacter pylori with nitazoxanide-based therapy after eight treatment failures | 0.5 | 0 | Citations (PDF) |
| 777 | Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease | 4.4 | 0 | Citations (PDF) |
| 778 | Non‐Bismuth Quadruple Concomitant Treatment for
Helicobacter pylori
Eradication: A Systematic Review and Meta‐Analysis | 3.8 | 2 | Citations (PDF) |
| 779 | Review Article: Classic Bismuth Quadruple Therapy for
Helicobacter pylori
Infection—Questions Focused on Clinical Practice | 3.7 | 1 | Citations (PDF) |
| 780 | GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease | 3.2 | 1 | Citations (PDF) |
| 781 |
Helicobacter pylori
Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort | 3.8 | 0 | Citations (PDF) |
| 782 | Efectividad de los tratamientos erradicadores de Helicobacter pylori en Atención Primaria: análisis de una cohorte nacional (oral) 0, , | | 0 | Citations (PDF) |
| 783 | Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds | 6.6 | 0 | Citations (PDF) |
| 784 | Successful eradication of multidrug-resistant Helicobacter pylori with nitazoxanide-based therapy after eight treatment failures | 0.1 | 0 | Citations (PDF) |
| 785 | 100 - MODELOS DE LENGUAJE DE GRAN TAMAÑO (LLM) Y HELICOBACTER PYLORI: EVALUACIÓN COMPARATIVA (BENCHMARK) Y AJUSTE FINO (FINETUNING) UTILIZANDO INFORMACIÓN DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HP-EUREG) | 0.5 | 0 | Citations (PDF) |
| 786 | 122 - PRESCRIPCIÓN DE TRATAMIENTOS PARA LA ERRADICACIÓN DE HELICOBACTER PYLORI EN ATENCIÓN PRIMARIA: DATOS DE UNA COHORTE NACIONAL CON MÁS DE 200.000 PACIENTES | 0.5 | 0 | Citations (PDF) |
| 787 | 101 - PRECISIÓN DIAGNÓSTICA DEL TEST DE ANTÍGENO EN HECES BASADO EN ANTICUERPOS MONOCLONALES PARA IDENTIFICAR HELICOBACTER PYLORI: REVISIÓN SISTEMÁTICA Y METAANÁLISIS | 0.5 | 0 | Citations (PDF) |
| 788 | 91 - PRECISIÓN DIAGNÓSTICA DEL TEST INMUNOQUÍMICO DE SANGRE OCULTA EN HECES PARA EVALUAR LA ACTIVIDAD ENDOSCÓPICA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL | 0.5 | 0 | Citations (PDF) |
| 789 | 113 - EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES DE HELICOBACTER PYLORI EN ATENCIÓN PRIMARIA: ANÁLISIS DE UNA COHORTE NACIONAL | 0.5 | 0 | Citations (PDF) |
| 790 | 108 - APRENDIZAJE AUTOMÁTICO CAUSAL PARA LA ESTIMACIÓN DEL EFECTO DEL TRATAMIENTO Y LA EVALUACIÓN DE ESTRATEGIAS EN TRATAMIENTOS EMPÍRICOS DE PRIMERA LÍNEA PARA LA ERRADICACIÓN DE HELICOBACTER PYLORI: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HP-EUREG) | 0.5 | 0 | Citations (PDF) |
